Hospital-based strategies to reduce antibiotic resistance: Are they valid in the community setting?

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 1, 2007, Pages 53-59

  Tillotson, Glenn S ^a   Blondeau, Joseph M ^b   Carroll, Joy ^c  

^a Replidyne Inc   (United States)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

^c Oscient Pharmaceuticals   (United States)

Author keywords

Antibiotic resistance; Community infections; Nosocomial pathogens

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; BRONCHITIS; COMMUNITY CARE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; DRUG USE; EDUCATION PROGRAM; GRAM NEGATIVE BACTERIUM; HEALTH EDUCATION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LOW DRUG DOSE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PYELONEPHRITIS; SHORT COURSE THERAPY; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL INFECTION; COMMUNICABLE DISEASE; CROSS INFECTION; DRUG EFFECT; GENETICS; PHYSIOLOGY; REVIEW; VALIDATION STUDY;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 85047697135     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.1.53     Document Type: Article

References (24)

1. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int. J. Antimicrob. Agents 17, 357-363 (2001).
2. Urbanek K, Kolar M, Strojil J et al. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol, Drug Saf. 14, 741-745 (2005).
3. Karlowsky J, Hoben DJ, DeCorby MR et al. Fluoroquinolone resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob. Agents Chemother. 50, 2251-2254 (2006).
4. Garcia-Rey C, Aguilar L, Baquero F et al. Pharmacoepidmiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J. Clin. Microbiol. 40, 2959-2963 (2002).
5. Kolar M, Urbanek K, Vagnerova I, Koulkalova D. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J. Clin. Pharm. Ther. 31, 67-72 (2006).
6. Talbot GH, Bradley J, Edwards JE et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis.. 42, 657-668 (2006).
7. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections. Drugs 20, 2157-2168 (2003).
8. Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J. Antimicrob. Chemother, 55(1), 6-9 (2005).
9. Bonten MJ, Weinstein RA. Antibiotic cycling in intensive care units: the value of organized chaos? Crit. Care Med. 34(2), 549-551 (2006).
10. Raymond DP, Pelletier SJ, Sawyer RG Antibiotic utilization strategies to limit antimicrobial resistance. Semin. Respir. Crit. Care Med. 23(5), 497-501 (2002).
11. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. 111 (Suppl. 9A), 19S-24S (2001).
12. File TM Jr, Garau, J, Blasi F et al Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125(5), 1888-1901 (2004).
13. Pletz MWR, Shergill AP, McGee L et al. Prevalence of first step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob. Ag. Chemother. 50, 1561-1563 (2006).
14. Brennan TA, Rothman DJ, Blank L et al. Health industry practices that create conflicts of interest. JAMA 295, 429-433 (2006).
15. Kopelow M. ACCME at the Alliance. Presented at Annual Meeting of ACCME. FL, USA (2005).
16. Pamparana F. The rationale for "use best first": introduction to the proceedings. J. Chemother. 18, 7-8 (2006).
17. Singh N, Rogers P, Atwood CW et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am. J. Resp. Crit. Care Med. 162, 505-511 (2000).
18. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 29(6), 1109-1115 (2001).
19. National Disease and Therapeutic Index. Antibiotic usage in USA. December (2005).
20. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 279(5), 365-370 (1998).
21. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286(1), 49-56 (2001).
22. File TM Jr. Shorter course therapy of serious respiratory infections: new data for new approaches to management. Curr. Opin. Infect. Dis. 17(2), 105-107 (2004).
23. Gafter-Gvili A, Fraser A. Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann. Intern. Med. 142(12 Pt 1), 979-995 (2005).
24. WHO. Report on Infectious Diseases 2000. Overcoming antibiotic resistance. WHO/CDS/ 2, 63 (2000).